Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Aldeyra Therapeutics, Inc. (ALDX) had Consolidated Net Income/Loss of $-3.45M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-3.45M |
|
-- |
|
-- |
|
$3.55M |
|
$-3.55M |
|
$0.09M |
|
$-3.45M |
|
$-3.45M |
|
$-3.45M |
|
$-3.45M |
|
|
Consolidated Net Income/Loss |
$-3.45M |
$-3.45M |
|
$-3.55M |
|
$-3.48M |
|
60.32M |
|
60.32M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$66.27M |
|
-- |
|
$0.21M |
|
$66.48M |
|
$24.33M |
|
-- |
|
-- |
|
$24.33M |
|
$42.16M |
|
$42.16M |
|
$42.16M |
|
60.32M |
|
| Cash Flow Statement Financials | |
$-5.11M |
|
-- |
|
$0.07M |
|
$70.04M |
|
$65.00M |
|
$-5.04M |
|
$-0.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.72 |
|
-- |
|
-- |
|
-- |
|
0.36 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.11M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.19% |
|
-8.19% |
|
-5.19% |
|
-8.19% |
|
$0.70 |
|
$-0.08 |
|
$-0.08 |
|